Metainflammation in Diabetic Coronary Artery Disease: Emerging Role of Innate and Adaptive Immune Responses

Journal of Diabetes Research

Volumn 2016, Issue , 2016, Pages

  Aravindhan, Vivekanandhan ^a   Madhumitha, Haridoss ^b  

^a UNIVERSITY OF MADRAS   (India)

^b ANNA UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; C TYPE LECTIN LIKE RECEPTOR; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 4; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 9; NOD1 LIKE RECEPTOR; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; RIG 1 LIKE RECEPTOR; RNA HELICASE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; LECTIN; RETINOIC ACID INDUCIBLE PROTEIN I;

ADAPTIVE IMMUNITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENDOTOXEMIA; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; INNATE IMMUNITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL; TH9 CELL; COMPLICATION; IMMUNOLOGY; T LYMPHOCYTE;

ADAPTIVE IMMUNITY; CORONARY ARTERY DISEASE; DEAD BOX PROTEIN 58; DIABETES MELLITUS, TYPE 2; HUMANS; IMMUNITY, INNATE; INFLAMMATION; LECTINS, C-TYPE; NLR PROTEINS; RECEPTORS, PATTERN RECOGNITION; T-LYMPHOCYTES; TH1 CELLS; TH17 CELLS; TH2 CELLS; TOLL-LIKE RECEPTORS;

EID: 84984689006     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2016/6264149     Document Type: Review

References (101)

1. D. Aronson and E. R. Edelman, "Coronary artery disease and diabetes mellitus," Heart Failure Clinics, vol. 12, no. 1, pp. 117-133, 2016.
2. F. Laugerette, C. Vors, N. Peretti, and M.-C. Michalski, "Complex links between dietary lipids, endogenous endotoxins and metabolic inflammation," Biochimie, vol. 93, no. 1, pp. 39-45, 2011.
3. W. Ebstein, "Invited comment on W. Ebstein: on the therapy of diabetes mellitus, in particular on the application of sodium salicylate," Journal of Molecular Medicine, vol. 80, no. 10, pp. 618-619, 2002.
4. N. Dali-Youcef, M. Mecili, R. Ricci, and E. Andrès, "Metabolic inflammation: connecting obesity and insulin resistance," Annals of Medicine, vol. 45, no. 3, pp. 242-253, 2013.
5. D. Tousoulis, M. Charakida, and C. Stefanadis, "Endothelial function and inflammation in coronary artery disease," Heart, vol. 92, no. 4, pp. 441-444, 2006.
6. M. S. Shah and M. Brownlee, "Molecular and cellular mechanisms of cardiovascular disorders in diabetes," Circulation Research, vol. 118, no. 11, pp. 1808-1829, 2016.
7. R. Virmani, A. P. Burke, and F. Kolodgie, "Morphological characteristics of coronary atherosclerosis in diabetes mellitus," The Canadian Journal of Cardiology, vol. 22, pp. 81B-84B, 2006.
8. M. Naghavi, P. Libby, E. Falk et al., "Fromvulnerable plaque to vulnerable patient: a call for newdefinitions and risk assessment strategies: part I," Circulation, vol. 108, no. 14, pp. 1664-1672, 2003.
9. R. Ross, "Atherosclerosis-an inflammatory disease," The New England Journal of Medicine, vol. 340, no. 2, pp. 115-126, 1999.
10. J. Danesh, R. Collins, and R. Peto, "Chronic infections and coronary heart disease: is there a link" The Lancet, vol. 350, no. 9075, pp. 430-436, 1997.
11. T. Kawai and S. Akira, "The roles of TLRs, RLRs and NLRs in pathogen recognition," International Immunology, vol. 21, no. 4, pp. 317-337, 2009.
12. O. Takeuchi and S. Akira, "Pattern recognition receptors and inflammation," Cell, vol. 140, no. 6, pp. 805-820, 2010.
13. V. Aravindhan, V. Mohan, J. Surendar et al., "Effect of filarial infection on serum inflammatory and atherogenic biomarkers in coronary artery disease (CURES-121)," The American Journal of Tropical Medicine and Hygiene, vol. 86, no. 5, pp. 828-833, 2012.
14. V. Aravindhan, V. Mohan, J. Surendar et al., "Decreased prevalence of lymphatic filariasis among diabetic subjects associated with a diminished pro-inflammatory cytokine response (CURES 83)," PLoS Neglected Tropical Diseases, vol. 4, no. 6, article e707, 2010.
15. J. Surendar, V. Aravindhan, M. M. Rao, A. Ganesan, and V. Mohan, "Decreased serum interleukin-17 and increased transforming growth factor-αlevels in subjects with metabolic syndrome (Chennai Urban Rural Epidemiology Study-95)," Metabolism: Clinical and Experimental, vol. 60, no. 4, pp. 586-590, 2011.
16. K. Asehnoune, D. Strassheim, S. Mitra, J. Y. Kim, and E. Abraham, "Involvement of reactive oxygen species in tolllike receptor 4-dependent activation of NF-κB," The Journal of Immunology, vol. 172, no. 4, pp. 2522-2529, 2004.
17. H. Bilak, S. Tauszig-Delamasure, and J.-L. Imler, "Toll and Tolllike receptors in Drosophila," Biochemical Society Transactions, vol. 31, no. 3, pp. 648-651, 2003.
18. M. Gangloff, A. N. R. Weber, R. J. Gibbard, and N. J. Gay, "Evolutionary relationships, but functional differences, between the Drosophila and human Toll-like receptor families," Biochemical Society Transactions, vol. 31, no. 3, pp. 659-663, 2003.
19. F. Liu,W. Lu, Q. Qian,W. Qi, J. Hu, and B. Feng, "Frequency of TLR 2, 4, and 9 gene polymorphisms in Chinese population and their susceptibility to type 2 diabetes and coronary artery disease," Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 373945, 7 pages, 2012.
20. K. Singh, N. K. Agrawal, S. K. Gupta, G. Mohan, S. Chaturvedi, and K. Singh, "Increased expression of endosomalmembers of toll-like receptor family abrogates wound healing in patients with type 2 diabetes mellitus," International Wound Journal, 2015.
21. K. Ashida, K. Miyazaki, E. Takayama et al., "Characterization of the expression of TLR2 (toll-like receptor 2) and TLR4 on circulating monocytes in coronary artery disease," Journal of Atherosclerosis and Thrombosis, vol. 12, no. 1, pp. 53-60, 2005.
22. D. Pisetsky, "Cell death in the pathogenesis of immunemediated diseases: The role of HMGB1 and DAMP-PAMP complexes," Swiss Medical Weekly, vol. 141, Article ID w13256, 2011.
23. M. R. Dasu, S. Devaraj, S. Park, and I. Jialal, "Increased tolllike receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects," Diabetes Care, vol. 33, no. 4, pp. 861-868, 2010.
24. L. Branén, L. Hovgaard, M. Nitulescu, E. Bengtsson, J. Nilsson, and S. Jovinge, "Inhibition of tumor necrosis factor-αreduces atherosclerosis in apolipoprotein E knockoutmice," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 11, pp. 2137-2142, 2004.
25. M. J. Song, K. H. Kim, J. M. Yoon, and J. B. Kim, "Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes," Biochemical and Biophysical Research Communications, vol. 346, no. 3, pp. 739-745, 2006.
26. A. Alisi, N. Panera, and V. Nobili, "Toll-like receptor 4: a starting point for proinflammatory signals in fatty liver disease," Hepatology, vol. 51, no. 2, pp. 714-715, 2010.
27. R. A. Frost, G. J. Nystrom, and C. H. Lang, "Lipopolysaccharide stimulates nitric oxide synthase-2 expression in murine skeletal muscle and C2C12 myoblasts via Toll-like receptor-4 and c-Jun NH2-terminal kinase pathways," American Journal of Physiology-Cell Physiology, vol. 287, no. 6, pp. C1605-C1615, 2004.
28. H. Madhumitha, V. Mohan, N. P. Kumar, R. Pradeepa, S. Babu, and V. Aravindhan, "Impaired toll-like receptor signalling in peripheral B cells from newly diagnosed type-2 diabetic subjects," Cytokine, vol. 76, no. 2, pp. 253-259, 2015.
29. K. Edfeldt, J. Swedenborg, G. K. Hansson, and Z.-Q. Yan, "Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation," Circulation, vol. 105, no. 10, pp. 1158-1161, 2002.
30. M. B. Fessler, L. L. Rudel, and J. M. Brown, "Toll-like receptor signaling links dietary fatty acids to the metabolic syndrome," Current Opinion in Lipidology, vol. 20, no. 5, pp. 379-385, 2009.
31. J.-G. Wang and M. Aikawa, "Toll-like receptors and Src-family kinases in atherosclerosis-focus on macrophages," Circulation Journal, vol. 79, no. 11, pp. 2332-2334, 2015.
32. J. Brown, H. Wang, G. N. Hajishengallis, and M. Martin, "TLR-signaling networks: an integration of adaptor molecules, kinases, and cross-talk," Journal of Dental Research, vol. 90, no. 4, pp. 417-427, 2011.
33. P. J. Hertzog, L. A. O'Neill, and J. A. Hamilton, "The interferon in TLR signaling: more than just antiviral," Trends in Immunology, vol. 24, no. 10, pp. 534-539, 2003.
34. A. Zeytun, A. Chaudhary, P. Pardington, R. B. Cary, and G. Gupta, "Induction of cytokines and chemokines by tolllike receptor signaling: strategies for control of infammation," Critical Reviews in Immunology, vol. 30, no. 1, pp. 53-67, 2010.
35. R. Samarasinghe, P. Tailor, T. Tamura, T. Kaisho, S. Akira, and K. Ozato, "Induction of an anti-inflammatory cytokine, IL-10, in dendritic cells after toll-like receptor signaling," Journal of Interferon & Cytokine Research, vol. 26, no. 12, pp. 893-900, 2006.
36. J. Chang, S. L. Kunkel, and C.-H. Chang, "Negative regulation of MyD88-dependent signaling by IL-10 in dendritic cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 43, pp. 18327-18332, 2009.
37. L. Franchi, N. Warner, K. Viani, and G. Nuñez, "Function of Nod-like receptors in microbial recognition and host defense," Immunological Reviews, vol. 227, no. 1, pp. 106-128, 2009.
38. H. Tada, S. Aiba, K.-I. Shibata, T. Ohteki, and H. Takada, "Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells," Infection and Immunity, vol. 73, no. 12, pp. 7967-7976, 2005.
39. E. Voss, J. Wehkamp, K. Wehkamp, E. F. Stange, J. M. Schröder, and J. Harder, "NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2," The Journal of Biological Chemistry, vol. 281, no. 4, pp. 2005-2011, 2006.
40. Y. Ogura, N. Inohara, A. Benito, F. F. Chen, S. Yamaoka, and G. Núñez, "Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-κB," The Journal of Biological Chemistry, vol. 276, no. 7, pp. 4812-4818, 2001.
41. J. H. Fritz, R. L. Ferrero, D. J. Philpott, and S. E. Girardin, "Nodlike proteins in immunity, inflammation and disease," Nature Immunology, vol. 7, no. 12, pp. 1250-1257, 2006.
42. H. Wen, E. A. Miao, and J. P.-Y. Ting, "Mechanisms of NODlike receptor-associated inflammasome activation," Immunity, vol. 39, no. 3, pp. 432-441, 2013.
43. T. Watanabe, N. Asano, A. Kitani, I. J. Fuss, T. Chiba, and W. Strober, "Activation of type I IFN signaling by NOD1 mediates mucosal host defense against Helicobacter pylori infection," Gut Microbes, vol. 2, no. 1, pp. 61-65, 2011.
44. B. Prajapati, P. K. Jena, P. Rajput, K. Purandhar, and S. Seshadri, "Understanding and modulating the Toll like Receptors (TLRs) and NOD like Receptors (NLRs) cross talk in type 2 diabetes," Current Diabetes Reviews, vol. 10, no. 3, pp. 190-200, 2014.
45. L. Zhao, P. Hu, Y. Zhou, J. Purohit, and D. Hwang, "NOD1 activation induces proinflammatory gene expression and insulin resistance in 3T3-L1 adipocytes," American Journal of Physiology-Endocrinology and Metabolism, vol. 301, no. 4, pp. E587-E598, 2011.
46. A. K. Tamrakar, J. D. Schertzer, T. T. Chiu et al., "NOD2 activation induces muscle cell-autonomous innate immune responses and insulin resistance," Endocrinology, vol. 151, no. 12, pp. 5624-5637, 2010.
47. X. Wan, C. Xu, Y. Lin et al., "Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasomedependentmechanism," Journal ofHepatology, vol. 64,no. 4, pp. 925-932, 2016.
48. A. Shiny, B. Regin, V. Balachandar et al., "Convergence of innate immunity and insulin resistance as evidenced by increased nucleotide oligomerization domain (NOD) expression and signaling in monocytes from patients with type 2 diabetes," Cytokine, vol. 64, no. 2, pp. 564-570, 2013.
49. J. D. Schertzer, A. K. Tamrakar, J. G. Magalhães et al., "NOD1 activators link innate immunity to insulin resistance," Diabetes, vol. 60, no. 9, pp. 2206-2215, 2011.
50. P. Prieto, M. T. Vallejo-Cremades, G. Benito et al., "NOD1 receptor is up-regulated in diabetic human and murine myocardium," Clinical Science, vol. 127, no. 12, pp. 665-677, 2014.
51. J. D. Laman, A. H. Schoneveld, F. L. Moll, M. VanMeurs, and G. Pasterkamp, "Significance of peptidoglycan, a proinflammatory bacterial antigen in atherosclerotic arteries and its association with vulnerable plaques," American Journal of Cardiology, vol. 90, no. 2, pp. 119-123, 2002.
52. H. Nishio, S. Kanno, S. Onoyama et al., "Nod1 ligands induce site-specific vascular inflammation," Arteriosclerosis,Thrombosis, and Vascular Biology, vol. 31, no. 5, pp. 1093-1099, 2011.
53. M. Fernández-Velasco, P. Prieto, V. Terrón et al., "NOD1 activation induces cardiac dysfunction and modulates cardiac fibrosis and cardiomyocyte apoptosis," PLoS ONE, vol. 7, no. 9, Article ID e45260, 2012.
54. Y. Pan, G. Li, H. Zhong et al., "RIG-I inhibits pancreatic cell proliferation through competitive binding of activated Src," Scientific Reports, vol. 6, Article ID28914, 2016.
55. A. Komuro, D. Bamming, and C. M. Horvath, "Negative regulation of cytoplasmic RNA-mediated antiviral signaling," Cytokine, vol. 43, no. 3, pp. 350-358, 2008.
56. T. B. H. Geijtenbeek and S. I. Gringhuis, "Signalling through C-type lectin receptors: shaping immune responses," Nature Reviews Immunology, vol. 9, no. 7, pp. 465-479, 2009.
57. S. Iborra and D. Sancho, "Signalling versatility following self and non-self sensing by myeloid C-type lectin receptors," Immunobiology, vol. 220, no. 2, pp. 175-184, 2015.
58. M. Ichioka, T. Suganami, N. Tsuda et al., "Increased expression of macrophage-inducible C-type lectin in adipose tissue of obese mice and humans," Diabetes, vol. 60, no. 3, pp. 819-826, 2011.
59. A. L. Neves, J. Coelho, L. Couto, A. Leite-Moreira, and R. Roncon-Albuquerque Jr., "Metabolic endotoxemia: amolecular link between obesity and cardiovascular risk," Journal of Molecular Endocrinology, vol. 51, no. 2, pp. R51-R64, 2013.
60. S. deKort, D. Keszthelyi, and A. A. M. Masclee, "Leaky gut and diabetes mellitus: what is the link" Obesity Reviews, vol. 12, no. 6, pp. 449-458, 2011.
61. V. Aravindhan, V. Mohan, H. Madhumitha, S. Valarmathi, and S. Babu, "Increased levels of endotoxin core antibodies and decreased levels of sCD 14 indicate chronic endotoxemia in coronary artery disease (CURES-127)," Journal of Clinical & Experimental Cardiology, vol. 4, no. 9, article 264, 2013.
62. P. D. Cani, J. Amar, M. A. Iglesias et al., "Metabolic endotoxemia initiates obesity and insulin resistance," Diabetes, vol. 56, no. 7, pp. 1761-1772, 2007.
63. M. Manco, L. Putignani, and G. F. Bottazzo, "Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk," Endocrine Reviews, vol. 31, no. 6, pp. 817-844, 2010.
64. L. Jonasson, J. Holm,O. Skalli, G. Bondjers, andG. K. Hansson, "Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque," Arteriosclerosis, vol. 6, no. 2, pp. 131-138, 1986.
65. J. Surendar, V. Mohan, N. Pavankumar, S. Babu, andV. Aravindhan, "Increased levels of serum granulocyte-macrophage colony-stimulating factor is associated with activated peripheral dendritic cells in type 2 diabetes subjects (CURES-99)," Diabetes Technology andTherapeutics, vol. 14, no. 4, pp. 344-349, 2012.
66. S. Tangvarasittichai, S. Pongthaisong, and O. Tangvarasittichai, "Tumor necrosis factor-, interleukin-6, C-reactive protein levels and insulin resistance associated with type 2 diabetes in abdominal obesity women," Indian Journal of Clinical Biochemistry, vol. 31, no. 1, pp. 68-74, 2016.
67. J. Spranger, A. Kroke,M. Möhlig et al., "Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study," Diabetes, vol. 52, no. 3, pp. 812-817, 2003.
68. A. M. Miller, "Role of IL-33 in inflammation and disease," Journal of Inflammation, vol. 8, no. 1, article 22, 2011.
69. P. Miossec and J. K. Kolls, "Targeting IL-17 and TH17 cells in chronic inflammation," Nature Reviews Drug Discovery, vol. 11, no. 10, pp. 763-776, 2012.
70. A. Shimbara, P. Christodoulopoulos, A. Soussi-Gounni et al., "IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma," Journal of Allergy and Clinical Immunology, vol. 105, no. 1, pp. 108-115, 2000.
71. J. Louten, A. L. Rankin, Y. Li et al., "Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation," International Immunology, vol. 23, no. 5, pp. 307-315, 2011.
72. Y. Y. Wan, "Multi-tasking of helper T cells," Immunology, vol. 130, no. 2, pp. 166-171, 2010.
73. L. Pacifico, L. Di Renzo, C. Anania et al., "Increased T-helper interferon-β-secreting cells in obese children," European Journal of Endocrinology, vol. 154, no. 5, pp. 691-697, 2006.
74. M. Wegner, H. Winiarska, T. Bobkiewicz-Kozowska, and M. Dworacka, "IL-12 serum levels in patients with type 2 diabetes treated with sulphonylureas," Cytokine, vol. 42, no. 3, pp. 312-316, 2008.
75. J. Surendar, V. Mohan, M. M. Rao, S. Babu, and V. Aravindhan, "Increased levels of both Th1 andTh2 cytokines in subjects with metabolic syndrome (CURES-103)," Diabetes Technology and Therapeutics, vol. 13, no. 4, pp. 477-482, 2011.
76. U. Kintscher, M. Hartge, K. Hess et al., "T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 7, pp. 1304-1310, 2008.
77. F. C. McGillicuddy, E. H. Chiquoine, C. C. Hinkle et al., "Interferon attenuates insulin signaling, lipid storage, and differentiation in human adipocytes via activation of the JAK/STAT pathway," The Journal of Biological Chemistry, vol. 284, no. 46, pp. 31936-31944, 2009.
78. J. E. McLaren and D. P. Ramji, "Interferon gamma: amaster regulator of atherosclerosis," Cytokine and Growth Factor Reviews, vol. 20, no. 2, pp. 125-135, 2009.
79. L. Jonasson, J. Holm,O. Skalli, G. Gabbiani, andG. K. Hansson, "Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis," The Journal of Clinical Investigation, vol. 76, no. 1, pp. 125-131, 1985.
80. J. Frostegard, A.-K. Ulfgren, P. Nyberg et al., "Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines," Atherosclerosis, vol. 145, no. 1, pp. 33-43, 1999.
81. S. Gupta, A. M. Pablo, X.-C. Jiang, N. Wang, A. R. Tall, and C. Schindler, "IFN-gamma potentiates atherosclerosis in ApoE knock-out mice," The Journal of Clinical Investigation, vol. 99, no. 11, pp. 2752-2761, 1997.
82. W. A. LaFramboise, R. Dhir, L. A. Kelly et al., "Serum protein profiles predict coronary artery disease in symptomatic patients referred for coronary angiography," BMC Medicine, vol. 10, article 157, 2012.
83. H. Madhumitha, V. Mohan, M. Deepa, S. Babu, and V. Aravindhan, "IncreasedTh1 and suppressedTh2serumcytokine levels in subjects with diabetic coronary artery disease," Cardiovascular Diabetology, vol. 13, article 1, 2014.
84. L. Q. Jiang, N. Franck, B. Egan et al., "Autocrine role of interleukin-13 on skeletal muscle glucose metabolism in type 2 diabetic patients involves microRNA let-7," American Journal of Physiology-Endocrinology and Metabolism, vol. 305, no. 11, pp. E1359-E1366, 2013.
85. Y.-H. Chang, K.-T. Ho, S.-H. Lu, C.-N. Huang, and M.-Y. Shiau, "Regulation of glucose/lipid metabolism and insulin sensitivity by interleukin-4," International Journal of Obesity, vol. 36, no. 7, pp. 993-998, 2012.
86. S. Winer, Y. Chan, G. Paltser et al., "Normalization of obesityassociated insulin resistance through immunotherapy," Nature Medicine, vol. 15, no. 8, pp. 921-929, 2009.
87. G. Anand, R. Vasanthakumar, V. Mohan, S. Babu, and V. Aravindhan, "Increased IL-12 and decreased IL-33 serum levels are associated with increased Th1 and suppressedTh2 cytokine profile in patients with diabetic nephropathy (CURES-134)," International Journal of Clinical and Experimental Pathology, vol. 7, no. 11, pp. 8008-8015, 2015.
88. Z. Mallat, S. Taleb, H. Ait-Oufella, and A. Tedgui, "The role of adaptive T cell immunity in atherosclerosis," Journal of Lipid Research, vol. 50, pp. S364-S369, 2009.
89. J. L. Fernandes, R. L. Mamoni, J. L. Orford et al., "IncreasedTh1 activity in patients with coronary artery disease," Cytokine, vol. 26, no. 3, pp. 131-137, 2004.
90. L. A. Tesmer, S. K. Lundy, S. Sarkar, and D. A. Fox, "Th17 cells in human disease," Immunological Reviews, vol. 223, no. 1, pp. 87-113, 2008.
91. P. Kumar, K. Natarajan, and N. Shanmugam, "High glucose driven expression of pro-inflammatory cytokine and chemokine genes in lymphocytes: molecularmechanisms of IL-17 family gene expression," Cellular Signalling, vol. 26, no. 3, pp. 528-539, 2014.
92. M. K. Arababadi, R. Nosratabadi, G. Hassanshahi et al., "Nephropathic complication of type-2 diabetes is following pattern of autoimmune diseases" Diabetes Research and Clinical Practice, vol. 87, no. 1, pp. 33-37, 2010.
93. R. Vasanthakumar, V. Mohan, G. Anand, M. Deepa, S. Babu, and V. Aravindhan, "Serum IL-9, IL-17, and TGF-αlevels in subjects with diabetic kidney disease (CURES-134)," Cytokine, vol. 72, no. 1, pp. 109-112, 2015.
94. N. Afzal, K. Javaid,W. Sami et al., "Inverse relationship of serum IL-17with type-II diabetes retinopathy," Clinical Laboratory, vol. 59, no. 11-12, pp. 1311-1317, 2013.
95. E. Smith, K.-M. R. Prasad, M. Butcher et al., "Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice," Circulation, vol. 121, no. 15, pp. 1746-1755, 2010.
96. C. Erbel, T. J. Dengler, S. Wangler et al., "Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability," Basic Research in Cardiology, vol. 106, no. 1, pp. 125-134, 2011.
97. J. Xing, Y. Wu, and B. Ni, "Th9: a new player in asthma pathogenesis" Journal of Asthma, vol. 48, no. 2, pp. 115-125, 2011.
98. H. Hang, S. Yuan,Q. Yang, D. Yuan, andQ. Liu, "Multiplex bead array assay of plasma cytokines in type 2 diabetes mellitus with diabetic retinopathy," Molecular Vision, vol. 20, pp. 1137-1145, 2014.
99. W. Zhang, T. Tang, D. Nie et al., "IL-9 aggravates the development of atherosclerosis in ApoE/ mice," Cardiovascular Research, vol. 106, no. 3, pp. 453-464, 2015.
100. I. Gregersen, M. Skjelland, S. Holm et al., "Increased systemic and local interleukin 9 levels in patients with carotid and coronary atherosclerosis," PLoS ONE, vol. 8, no. 8, Article ID e72769, 2013.
101. D. Mathis and S. E. Shoelson, "Immunometabolism: an emerging frontier," Nature Reviews Immunology, vol. 11, no. 2, pp. 81-83, 2011.